Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non Operating Income (2016 - 2025)

Catalyst Pharmaceuticals' Non Operating Income history spans 12 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 11.32% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $25.7 million, up 21.75%, while the annual FY2025 figure was $25.7 million, 21.75% up from the prior year.
  • Non Operating Income reached $10.1 million in Q4 2025 per CPRX's latest filing, up from $4.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.3 million in Q4 2024 to a low of -$833000.0 in Q3 2023.
  • Average Non Operating Income over 5 years is $2.9 million, with a median of $1.8 million recorded in 2023.
  • The largest YoY upside for Non Operating Income was 3008.45% in 2022 against a maximum downside of 622.58% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $71000.0 in 2021, then skyrocketed by 3008.45% to $2.2 million in 2022, then soared by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then fell by 11.32% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Non Operating Income are $10.1 million (Q4 2025), $4.8 million (Q3 2025), and $3.0 million (Q2 2025).